Top

Diabetologia

Published in:

Open Access 01-03-2019 | Article

Tetraspanin 7 autoantibodies predict progressive decline of beta cell function in individuals with LADA

Authors: Xiajie Shi, Gan Huang, Yanfei Wang, Zhenqi Liu, Chao Deng, Xia Li, Peilin Zheng, Zhiguang Zhou

Published in: Diabetologia | Issue 3/2019

Abstract

Aims/hypothesis

The aim of this work was to investigate whether tetraspanin 7 autoantibodies (TSPAN7A) are valuable in predicting poor beta cell function in individuals with latent autoimmune diabetes in adults (LADA).

Methods

The cross-sectional study involved participants with LADA (n = 173), type 1 diabetes (n = 158), type 2 diabetes (n = 204) and healthy control participants (n = 170). The longitudinal study involved 53 participants with LADA, with a 3-year follow-up. In both cohorts, TSPAN7A in the sera were measured by a luciferase immunoprecipitation system assay, and physical and clinical characteristics were recorded.

Results

The prevalence of TSPAN7A in LADA, type 1 diabetes, type 2 diabetes and healthy control participants was 21.4% (37/173), 26% (41/158), 0.5% (1/204) and 1.2% (2/170), respectively. Importantly, measurement of TSPAN7A significantly increased the number of individuals with LADA found to be positive for multiple antibodies (32.4% vs 22%; p < 0.001). Further logistic regression analysis demonstrated that positivity for TSPAN7A (OR 2.87, p = 0.034), disease duration (OR 1.83, p = 0.019) and GAD antibody titre (OR 2.67, p = 0.009) were risk factors for beta cell function in LADA, while BMI (OR 0.34, p = 0.001) was a protective factor. In the prospective study in individuals with LADA, the median annual decrease in rates of fasting C-peptide and 2 h postprandial C-peptide in individuals who were positive for TSPAN7A was significantly higher when compared with the decrease in those who were negative for TSPAN7A (34.6% vs 7.9%, p = 0.043 and 33.2% vs 11%, p = 0.041, respectively).

Conclusions/interpretation

TSPAN7A are valid islet autoantibodies for use in East Asian populations with autoimmune diabetes and can discriminate individuals with LADA who have lower beta cell function after disease progression.

Available only for authorised users

Zhou Z, Xiang Y, Ji L et al (2013) Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes 62(2):543–550. https://doi.org/10.2337/db12-0207 CrossRefPubMedPubMedCentral

Mishra R, Chesi A, Cousminer DL et al (2017) Relative contribution of type 1 and type 2 diabetes loci to the genetic etiology of adult-onset, non-insulin-requiring autoimmune diabetes. BMC Med 15(1):88. https://doi.org/10.1186/s12916-017-0846-0 CrossRefPubMedPubMedCentral

Zhao Y, Yang L, Xiang Y et al (2014) Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab 99(5):E876–E880. https://doi.org/10.1210/jc.2013-3633 CrossRefPubMed

Luo S, Lin J, Xie Z et al (2016) HLA genetic discrepancy between latent autoimmune diabetes in adults and type 1 diabetes: LADA China study No. 6. J Clin Endocrinol Metab 101(4):1693–1700. https://doi.org/10.1210/jc.2015-3771 CrossRefPubMed

McLaughlin KA, Richardson CC, Ravishankar A et al (2016) Identification of tetraspanin-7 as a target of autoantibodies in type 1 diabetes. Diabetes 65(6):1690–1698. https://doi.org/10.2337/db15-1058 CrossRefPubMed

Walther D, Eugster A, Jergens S et al (2016) Tetraspanin 7 autoantibodies in type 1 diabetes. Diabetologia 59(9):1973–1976. https://doi.org/10.1007/s00125-016-3997-1 CrossRefPubMed

Menager MM (2017) TSPAN7, effector of actin nucleation required for dendritic cell-mediated transfer of HIV-1 to T cells. Biochem Soc Trans 45(3):703–708. https://doi.org/10.1042/BST20160439 CrossRefPubMed

Hald J, Galbo T, Rescan C et al (2012) Pancreatic islet and progenitor cell surface markers with cell sorting potential. Diabetologia 55(1):154–165. https://doi.org/10.1007/s00125-011-2295-1 CrossRefPubMed

Aanstoot HJ, Kang SM, Kim J et al (1996) Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes. J Clin Invest 97(12):2772–2783. https://doi.org/10.1172/JCI118732 CrossRefPubMedPubMedCentral

10.

Winnock F, Christie MR, Batstra MR et al (2001) Autoantibodies to a 38-kDa glycosylated islet cell membrane-associated antigen in (pre)type 1 diabetes: association with IA-2 and islet cell autoantibodies. Diabetes Care 24(7):1181–1186. https://doi.org/10.2337/diacare.24.7.1181 CrossRefPubMed

11.

Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15(7):539–553. https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S CrossRef

12.

Deng C, Xiang Y, Tan T et al (2016) Altered peripheral B-lymphocyte subsets in type 1 diabetes and latent autoimmune diabetes in adults. Diabetes Care 39(3):434–440. https://doi.org/10.2337/dc15-1765 CrossRefPubMed

13.

Huang G, Xiang Y, Pan L, Li X, Luo S, Zhou Z (2013) Zinc transporter 8 autoantibody (ZnT8A) could help differentiate latent autoimmune diabetes in adults (LADA) from phenotypic type 2 diabetes mellitus. Diabetes Metab Res Rev 29(5):363–368. https://doi.org/10.1002/dmrr.2396 CrossRefPubMed

14.

Huang G, Yin M, Xiang Y et al (2016) Persistence of glutamic acid decarboxylase antibody (GADA) is associated with clinical characteristics of latent autoimmune diabetes in adults: a prospective study with 3-year follow-up. Diabetes Metab Res Rev 32(6):615–622. https://doi.org/10.1002/dmrr.2779 CrossRefPubMed

15.

Burbelo PD, Hirai H, Issa AT et al (2010) Comparison of radioimmunoprecipitation with luciferase immunoprecipitation for autoantibodies to GAD65 and IA-2β. Diabetes Care 33(4):754–756. https://doi.org/10.2337/dc09-1938 CrossRefPubMedPubMedCentral

16.

Ling Y, Jiang P, Li N, Yan Q, Wang X (2018) A luciferase immunoprecipitation assay for the detection of proinsulin/insulin autoantibodies. Clin Biochem 54:51–55. https://doi.org/10.1016/j.clinbiochem.2018.02.011 CrossRefPubMed

17.

Lampasona V, Petrone A, Tiberti C et al (2010) Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: non insulin requiring autoimmune diabetes (NIRAD) 4. Diabetes Care 33(1):104–108. https://doi.org/10.2337/dc08-2305 CrossRefPubMed

18.

Burbelo PD, Hirai H, Leahy H et al (2008) A new luminescence assay for autoantibodies to mammalian cell-prepared insulinoma-associated protein 2. Diabetes Care 31(9):1824–1826. https://doi.org/10.2337/dc08-0286 CrossRefPubMedPubMedCentral

19.

Lindskog C, Asplund A, Engkvist M, Uhlen M, Korsgren O, Ponten F (2010) Antibody-based proteomics for discovery and exploration of proteins expressed in pancreatic islets. Discov Med 9:565–578PubMed

20.

Notkins AL, Zhang B, Matsumoto Y, Lan MS (1997) Comparison of IA-2 with IA-2β and with six other members of the protein tyrosine phosphatase family: recognition of antigenic determinants by IDDM sera. J Autoimmun 10(3):245–250. https://doi.org/10.1006/jaut.1997.0132 CrossRefPubMed

21.

Chimienti F, Devergnas S, Favier A, Seve M (2004) Identification and cloning of a β-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes 53(9):2330–2337. https://doi.org/10.2337/diabetes.53.9.2330 CrossRefPubMed

22.

Buzzetti R, Zampetti S, Maddaloni E (2017) Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol 13(11):674–686. https://doi.org/10.1038/nrendo.2017.99 CrossRefPubMed

23.

Miao D, Guyer KM, Dong F et al (2013) GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes. Diabetes 62(12):4174–4178. https://doi.org/10.2337/db13-0534 CrossRefPubMedPubMedCentral

24.

Yu L, Miao D, Scrimgeour L, Johnson K, Rewers M, Eisenbarth GS (2012) Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay. Diabetes 61(1):179–186. https://doi.org/10.2337/db11-0670 CrossRefPubMed

25.

Krause S, Landherr U, Agardh CD et al (2014) GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial. Diabetes Care 37(6):1675–1680. https://doi.org/10.2337/dc13-1719 CrossRefPubMed

26.

Mayr A, Schlosser M, Grober N et al (2007) GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes 56(6):1527–1533. https://doi.org/10.2337/db06-1715 CrossRefPubMed

27.

Juusola M, Parkkola A, Harkonen T et al (2016) Positivity for zinc transporter 8 autoantibodies at diagnosis is subsequently associated with reduced β-cell function and higher exogenous insulin requirement in children and adolescents with type 1 diabetes. Diabetes Care 39(1):118–121. https://doi.org/10.2337/dc15-1027 CrossRefPubMed

28.

Jones AG, Hattersley AT (2013) The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 30(7):803–817. https://doi.org/10.1111/dme.12159 CrossRefPubMedPubMedCentral

29.

Andersen MK, Harkonen T, Forsblom C, Groop PH, Knip M, Tuomi T (2013) Zinc transporter type 8 autoantibodies (ZnT8A): prevalence and phenotypic associations in latent autoimmune diabetes patients and patients with adult onset type 1 diabetes. Autoimmunity 46(4):251–258. https://doi.org/10.3109/08916934.2012.741155 CrossRefPubMed

30.

Wang JP, Zhou ZG, Lin J et al (2007) Islet autoantibodies are associated with HLA-DQ genotypes in Han Chinese patients with type 1 diabetes and their relatives. Tissue Antigens 70(5):369–375. https://doi.org/10.1111/j.1399-0039.2007.00916.x CrossRefPubMed

31.

Yang L, Luo S, Huang G et al (2010) The diagnostic value of zinc transporter 8 autoantibody (ZnT8A) for type 1 diabetes in Chinese. Diabetes Metab Res Rev 26(7):579–584. https://doi.org/10.1002/dmrr.1128 CrossRefPubMedPubMedCentral

32.

Gorus FK, Balti EV, Messaaoui A et al (2017) Twenty-year progression rate to clinical onset according to autoantibody profile, age, and HLA-DQ genotype in a registry-based group of children and adults with a first-degree relative with type 1 diabetes. Diabetes Care 40(8):1065–1072. https://doi.org/10.2337/dc16-2228 CrossRefPubMed

33.

Krischer JP, Lynch KF, Schatz DA et al (2015) The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 58(5):980–987. https://doi.org/10.1007/s00125-015-3514-y CrossRefPubMedPubMedCentral

Title: Tetraspanin 7 autoantibodies predict progressive decline of beta cell function in individuals with LADA
Authors: Xiajie Shi
Gan Huang
Yanfei Wang
Zhenqi Liu
Chao Deng
Xia Li
Peilin Zheng
Zhiguang Zhou
Publication date: 01-03-2019
Publisher: Springer Berlin Heidelberg
Published in: Diabetologia / Issue 3/2019
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-018-4799-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 3/2019

One hour post-load plasma glucose and 3 year risk of worsening fasting and 2 hour glucose tolerance in the RISC cohort

Association and risk factors of chronic kidney disease and incident diabetes: a nationwide population-based cohort study

Type 2 diabetes mellitus, brain atrophy and cognitive decline in older people: a longitudinal study

Loss of X-box binding protein 1 in Müller cells augments retinal inflammation in a mouse model of diabetes

Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989–2013: a multicentre prospective registration study

Neoepitopes: a new take on beta cell autoimmunity in type 1 diabetes

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials